DEK over expression as an independent biomarker for poor prognosis in colorectal cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Lin, Lijuan ^a,b   Piao, Junjie ^a   Gao, Wenbin ^c   Piao, Yingshi ^a   Jin, Guang ^a   Ma, Yue ^a   Li, Jinzi ^a   Lin, Zhenhua ^a  

^a YANBIAN UNIVERSITY   (China)

^b EASTERN LIAONING UNIVERSITY   (China)

^c DALIAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; DEK; Immunohistochemistry; Survival analysis

Indexed keywords

DEK PROTEIN; NUCLEAR PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; DEK PROTEIN, HUMAN; NONHISTONE PROTEIN; ONCOPROTEIN;

ADULT; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DEK GENE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; SEROSA; SURVIVAL RATE; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; AGED; BIOSYNTHESIS; COLORECTAL TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; UPREGULATION;

ADULT; AGED; CHROMOSOMAL PROTEINS, NON-HISTONE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84880947578     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-366     Document Type: Article

References (35)

1. Hu HG, Scholten I, Gruss C, Knippers R. The distribution of the DEK protein in mammalian chromatin. Biochem Biophys Res Commun 2007, 358(4):1008-1014. 10.1016/j.bbrc.2007.05.019, 17524367.
2. Privette Vinnedge LM, Ho SM, Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone recepter signaling in breast cancer. PLoS One 2012, 7(10):e46985. 10.1371/journal.pone.0046985, 3468546, 23071688.
3. Riveiro-Falkenbach E, Soengas MS. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 2010, 16(11):2932-2938. 10.1158/1078-0432.CCR-09-2330, 2931273, 20501624.
4. von Lindern M, Fornerod M, van Baal S, Jaegle M, de Wit T, Buijs A, Grosveld G. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA. Mol Cell Biol 1992, 12(4):1687-1697. 369612, 1549122.
5. Fornerod M, Boer J, van Baal S, Jaeglé M, von Lindern M, Murti KG, Davis D, Bonten J, Buijs A, Grosveld G. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene 1995, 10(9):1739-1748.
6. Privette Vinnedge LM, Kappes F, Nassar N, Wells SI. Stacking the DEK from chromatin topology to cancer stem cell. Cell Cycle 2013, 12(1):51-66. 10.4161/cc.23121, 23255114.
7. Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol Cell Biol 2006, 26(20):7506-7519. 10.1128/MCB.00430-06, 1636856, 16894028.
8. Sitwala KV, Adams K, Markovitz DM. YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter. Oncogene 2002, 21(57):8862-8870. 10.1038/sj.onc.1206041, 12483538.
9. Lamond AI, Spector DL. Nuclear speckles: a model for nuclear organelles. Nat Rev Mol Cell Biol 2003, 4(8):605-612. 10.1038/nrm1172, 12923522.
10. Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI. Over expression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res 2009, 69(5):1792-1799. 10.1158/0008-5472.CAN-08-2304, 2650744, 19223548.
11. Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer 2011, 11:234. 10.1186/1471-2407-11-234, 3130704, 21663673.
12. Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z. Clinicopathological significance of DEK over expression in serous ovarian tumors. Pathol Int 2009, 59(7):443-447. 10.1111/j.1440-1827.2009.02392.x, 19563407.
13. Peng Y, Wang L, Gu J. Elevated preoperative Carcinoembryonic Antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer. World J Surg 2013, 37(1):208-213. 10.1007/s00268-012-1814-7, 23052808.
14. Goodarzi H, Elemento O, Tavazoie S. Revealing global regulatory perturbations across human cancers. Mol Cell 2009, 36(5):900-911. 10.1016/j.molcel.2009.11.016, 2900319, 20005852.
15. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009, 8(9):1367-1372. 10.4161/cc.8.9.8314, 19342874.
16. Hamilton SR, Aaltonen LA. World Health Organization Classification of Tumours-Pathology & Genetics Tumors of the digestive system Lyon, France: IARC press.
17. Compton CC. Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol 2003, 16(4):376-388. 10.1097/01.MP.0000062859.46942.93, 12692203.
18. Alwan A. World Health Organization. Disaster Med Public Health Prep 2007, 1(1):7-8.
19. Casas S, Nagy B, Elonen E, Aventín A, Larramendy ML, Sierra J, Ruutu T, Knuutila S. Aberrant expression of HOXA9, DEK, CBL and CSF1R in acute myeloid leukemia. Leuk Lymphoma 2003, 44(11):1935-1941. 10.1080/1042819031000119299, 14738146.
20. Larramendy ML, Niini T, Elonen E, Nagy B, Ollila J, Vihinen M, Knuutila S. Over expression of translocation-associated fusion genes of FGFRI, MYC, NPMI, and DEK, but absence of the translocations in acute myeloid leukemia. A microarray analysis. Haematologica 2002, 87(6):569-577.
21. Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, et al. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000, 156(2):191-198. 10.1016/S0304-3835(00)00462-6, 10880769.
22. Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, et al. Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res 1999, 59(19):4990-4996.
23. Kappes F, Khodadoust MS, Yu L, Kim DS, Fullen DR, Markovitz DM, Ma L. DEK expression in melanocytic lesions. Hum Pathol 2011, 42(7):932-938. 10.1016/j.humpath.2010.10.022, 3162348, 21316078.
24. Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Müller H. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006, 5(11):1202-1207. 10.4161/cc.5.11.2801, 16721057.
25. Orlic M, Spencer CE, Wang L, Gallie BL. Expression analysis of 6p22 genomic gain in retinoblastoma. Genes Chromosomes Cancer 2006, 45(1):72-82. 10.1002/gcc.20263, 16180235.
26. Paderova J, Orlic-Milacic M, Yoshimoto M, da Cunha SG, Gallie B, Squire JA. Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genet Cytogenet 2007, 179(2):102-111. 10.1016/j.cancergencyto.2007.08.014, 18036396.
27. Grasemann C, Gratias S, Stephan H, Schüler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A, et al. Gains and over expression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005, 24(42):6441-6449.
28. Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, Gruss C. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. Mol Cell Biol 2004, 24(13):6011-6020. 10.1128/MCB.24.13.6011-6020.2004, 480878, 15199154.
29. Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009, 69(16):6405-6413. 10.1158/0008-5472.CAN-09-1063, 2727675, 19679545.
30. Liu S, Wang X, Sun F, Kong J, Li Z, Lin Z. DEK over expression is correlated with the clinical features of breast cancer. Pathol Int 2012, 62(3):176-181. 10.1111/j.1440-1827.2011.02775.x, 22360505.
31. Babaei-Jadidi R, Li N, Saadeddin A, Spencer-Dene B, Jandke A, Muhammad B, Ibrahim EE, Muraleedharan R, Abuzinadah M, Davis H, et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation. J Exp Med 2011, 208(2):295-312. 10.1084/jem.20100830, 3039859, 21282377.
32. Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, et al. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res 2011, 39(17):7465-7476. 10.1093/nar/gkr454, 3177200, 21653549.
33. Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, et al. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene 2010, 29(33):4671-4681. 10.1038/onc.2010.217, 20543864.
34. Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A, et al. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007, 5(9):881-890. 10.1158/1541-7786.MCR-07-0055, 17855657.
35. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J Natl Cancer Inst 2004, 96(19):1420-1425. 10.1093/jnci/djh275, 15467030.